Real-world utilization of DMARDs and biologics in rheumatoid arthritis: The RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study

Current Medical Research and Opinion

Volumn 22, Issue 1, 2006, Pages 169-183

  Gibofsky, Allan ^a   Palmer, William R ^b   Goldman, John A ^c   Lautzenheiser, Richard L ^d   Markenson, Joseph A ^a   Weaver, Arthur ^e   Schiff, Michael H ^f   Keystone, Edward C ^g   Paulus, Harold E ^h   Harrison, Melanie J ^a   Whitmore, James B ⁱ   Leff, Jonathan A ⁱ  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b Westroads Medical Group   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Rheumatology Associates   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f Denver Arthritis Clinic PC   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ AMGEN INC   (United States)

Author keywords

Biologic; DMARD; Phase 4 clinical trial; Registry; Rheumatoid arthritis; TNF

Indexed keywords

ANTIRHEUMATIC AGENT; CHLOROQUINE; DAPSONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NEW DRUG; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; SULFALAZINE; TETRACYCLINE DERIVATIVE; THALIDOMIDE;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CLINICAL TRIAL; DEMOGRAPHY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EXPERIMENTAL THERAPY; FEMALE; GOLD THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRESCRIPTION; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PRESCRIPTIONS, DRUG; PROSPECTIVE STUDIES; REGISTRIES; TREATMENT OUTCOME;

EID: 30844470446     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X80341     Document Type: Article

References (36)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46:328-46
2. Sharp JT, Strand V, Leung H, et al. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis [Leflunomide Rheumatoid Arthritis Investigators Group]. Arthritis Rheum 2000;43:495-505
3. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New Engl J Med 2000;343:1586-93
4. Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 2001;28:1238-44
5. Lipsky P, Van der Heijde DMFM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. New Engl J Med 2000;343:1594-602
6. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204
7. van de Putte LBA, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004;63:508-16
8. Maetzel A, Bombardier C, Strand V, et al. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. J Rheumatol 1998;25:2331-8
9. Criswell LA, Such CL, Neuhaus JM, et al. Variation among rheumatologists in clinical outcomes and frequency of office visits for rheumatoid arthritis. J Rheumatol 1997;24:1266-71
10. Galindo-Rodriguez G, Avina-Zubieta JA, Fitzgerald A, et al. Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis. J Rheumatol 1997;24:633-8
11. Suarez-Almazor ME, Soskolne CL, Saunders LD, et al. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. J Rheumatol 1995;22:836-43
12. Berthelot JM, Saraux A, Maugars Y, et al. Is combination second-line therapy in rheumatoid arthritis more aggressive than helpful? Revue du Rhumatisme [English Ed.] 1999;66:224-8
13. McKendry RJ. The remarkable spectrum of methotrexate toxicities. Rheum Dis Clin North Am 1997;234:939-54
14. George CS, Lichtin AE. Hematologic complications of rheumatic disease therapies. Rheum Dis Clin North Am 1997;23:425-37
15. Balint G, Gergely Jr P. Clinical immunotoxicity of antirheumatic drugs. Inflamm Res 1996;45:S91-S95
16. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor α agents in rheumatoid arthritis. Arthritis Rheum 2003;48:313-8
17. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50
18. Byar DP, Simon RM, Friedewald WT, et al. Randomized clinical trials. Perspectives on some recent ideas. New Engl J Med 1976;295:74-80
19. Abel U, Koch A. The role of randomization in clinical studies: myths and beliefs. J Clin Epidemiol 1999;52:487-97
20. Sacks H, Chalmers TC, Smith Jr H. Randomized versus historical controls for clinical trials. Am J Med 1982;72:233-40
21. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I: medical. Stat Med 1989;8:441-54
22. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. New Engl J Med 2000;342:1878-86
23. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New Engl J Med 2000;342:1887-92
24. Steen KS, Lems WF, Aertsen J, et al. Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:443-7
25. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum 2000;43:522-30
26. Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999;26:2529-33
27. Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999;29:148-58
28. Gabriel SE, Crowson CS, O'Fallon WM. Comorbidity in arthritis. J Rheumatol 1999;26:2475-9
29. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93
30. Harrison MJ, Paulus HE, Mena HR, et al. Assessment of predictors of response to DMARD therapies in RA: real world experience in RADIUS [abstract]. Ann Rheum Dis 2005;64:189
31. Schiff M, Keystone E, Cush J, et al. Discontinuation of DMARD therapy in patients with rheumatoid arthritis enrolled in RADIUS 1 - rates, reasons, and predictors of early discontinuation [abstract]. Arthritis Rheum 2003;48:S336
32. Harrison MJ, Gibofsky A, Keystone E, et al. No change in treatment despite persistence of clinical activity in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2005;52:5720
33. Palmer WR, Markenson J, Garjian PA, et al. Update from the RADIUS 1 and 2 observational registries: safety outcomes with DMARD monotherapies and combination therapies [abstract]. Arthritis Rheum 2004;50:S560
34. Weaver A, Schiff M, Luetkemeyer J, et al. Real-world efficacy outcomes of monotherapies and combination therapies currently used in the treatment of rheumatoid arthritis - results from the RADIUS registries [abstract]. Arthritis Rheum 2004;50:S184-S185
35. Lautzenheiser RL, Gibofsky A, Shaw RA, et al. Efficacy in a real-world setting: rheumatoid arthritis patient outcomes [abstract]. Arthritis Rheum 2004;50:S699-S700
36. Weaver A, Lautzenheiser RL, Schiff MH, et al. Real-world effectiveness of select biolgic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. Curr Med Res Opin 2006;22:185-98